Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
Novavax announced that it has begun vaccinating healthy volunteers in the first human clinical trial of its virus-like particle (VLP) pandemic influenza vaccine.
The Phase I/IIa randomized, placebo-controlled clinical trial will evaluate the safety and immunogenicity of different doses of the H5N1 clade 2 VLP influenza vaccine in a maximum of 230 healthy adults, Novavax said.
The goals of the study are to demonstrate safety and to select a dose for evaluation in a
Phase IIb immunogenicity study, according to the company.
The company said it is developing vaccines to treat influenza and other viral diseases based upon VLP technology. The technology creates vaccine particles in cell culture that mimic the three-dimensional structure of the virus, but do not contain genetic material and cannot replicate, the company added.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May